upi.com
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce infections, operations, and long-term impact on the child and family.
Parents/caregivers of children with Crohn's disease, pediatric gastroenterologists, clinicians managing newly diagnosed pediatric IBD, and families considering biologic therapy.
What To Know
A new study reported in Gut and summarized by HealthDay/UPI found that early use of anti-TNF drugs (infliximab, adalimumab) in children newly diagnosed with Crohn's disease was associated with a much lower risk of developing anal fistulas.
The article cites an overall large reduction in fistula risk and an even greater reduction for kids who already had perianal skin tags, ulcers, or fissures. It notes anti-TNF drugs are more expensive than some other options (azathioprine, methotrexate) but suggests preventing fistulas could reduce downstream costs and surgeries such as ostomy placement.
This report describes observational study findings that starting anti-TNF therapy soon after diagnosis was linked to fewer perianal complications. It does not provide detailed study methods, absolute risks, or follow-up duration in the news story, and it does not substitute for individualized medical advice.
If you care for a child with Crohn's, discuss risks, benefits, timing, and insurance/access issues for biologic therapy with your gastroenterology team. Parents and caregivers of children with Crohn's disease, pediatric gastroenterologists, clinicians who treat newly diagnosed pediatric IBD patients, and families deciding about early biologic therapy.
The article is a news summary of a study published in Gut; it reports relative risk reductions but omits full study details such as design (observational vs randomized), confounding factors, and absolute event rates. Early treatment strategies can vary by patient and center; this story does not mean all children should start anti-TNF therapy immediately.
Reading the original Gut paper or discussing it with a clinician will provide needed detail.
This is a news summary of a study in Gut and reports large relative risk reductions but lacks full methodological details and absolute numbers. Observational findings need clinician interpretation before changing treatment. Cost and insurance access for anti-TNF drugs are practical considerations mentioned in the article.
